anti-TcdB (Clostridioides difficile extoxin) mAb (rec.) (VIF090-A6)

AdipoGen Life Sciences
Product Code: AG-27B-6333
Product Group: Primary Antibodies
CodeSizePrice
AG-27B-6333-C05050 ug£298.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1
Antibody Clonality: Recombinant Antibody
Antibody Clone: VIF090-A6
Regulatory Status: RUO
Target Species: Clostridioides species (bacteria)
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Functional Study
  • Western Blot (WB)
Shipping:
BLUE ICE
Storage:
Short Term: +4°C Long Term: -20°C

Further Information

Alternate Names/Synonyms:
Clostridioides Difficile Toxin B
Concentration:
1 mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.
Immunogen:
Recombinant TcdB (Clostridioides difficile, strain VPI10463) containing a C-terminal His-tag.
Long Description:
Recombinant Antibody. Recognizes TcdB from Clostridioides difficile. Applications: ELISA, FUNC, WB. Clone: VIF090-A6. Isotype: Human IgG1. Formulation: Liquid. In PBS. Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.
NCBI, Uniprot Number:
Q189K3
Other data:
This is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
Package Type:
Vial
Product Description:
Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.
Purity:
>95% (SDS-PAGE)
Source / Host:
Protein A purified from HEK293 cell culture supernatant.
Specificity:
Recognizes TcdB from Clostridioides difficile.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.Stable for at least 1 week when stored at +4°C.

References

Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile: V. Fuhner, et al.; Front. Microbiol. 9, 2908 (2018)